In this section you will find tools to help you better understand PNH and how SOLIRIS® (eculizumab) can help you treat the symptoms associated with this condition. These tools can also help you discuss PNH and SOLIRIS with your healthcare provider.
IMPORTANT SAFETY INFORMATION
SOLIRIS® increases the risk of meningococcal infections.
Patients should be vaccinated with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS. Revaccinate according to current medical guidelines for vaccine use.
Patients should be monitored closely for early signs of meningococcal infections and evaluated immediately if infection is suspected, and treated with antibiotics if necessary.
The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.
SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.
The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.
Please see important safety information (including boxed warning) as well as the complete prescribing information.